Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024
11 déc. 2024 06h00 HE
|
Enterome
Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite...
Enterome’s Immunotherapy EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular Lymphoma Suggesting a Potential Alternative to 'Watchful Waiting'
10 déc. 2024 11h43 HE
|
Enterome
46% objective response rate, with 15% complete responses and 31% partial responses in patients with early-stage follicular lymphoma reported at the ASH 2024 meeting.Well-tolerated treatment with no...
Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting
06 nov. 2024 06h00 HE
|
Enterome
Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monotherapy in a...
Enterome to Participate in the Jefferies Global Healthcare Conference
30 mai 2024 06h00 HE
|
Enterome
PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024
24 mai 2024 06h00 HE
|
Enterome
- Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab - ...
Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
25 avr. 2024 06h00 HE
|
Enterome
PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
17 avr. 2024 06h00 HE
|
Enterome
EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens...
Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024
06 mars 2024 06h42 HE
|
Enterome
PARIS, March 06, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors
18 déc. 2023 06h00 HE
|
Enterome
PARIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...
Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma
20 nov. 2023 06h00 HE
|
Enterome
Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual Meeting Median survival of 14.5 months and 18-months survival rate of 43.1% in a 26-patient cohort where EO2401 was...